Erdheim-Chester disease: 2026 so far

Benefits were reported more often, but toxicity still shaped care.

In the months covered, a larger real-world cohort across histiocytosis types, including ECD, added support for trametinib-based treatment. Many patients in that mixed cohort had clinical and imaging responses, but side effects were common and sometimes limited treatment; the ECD-specific reports that month were single-patient cases (2026-6). Over multiple months, case reports and small series repeatedly linked BRAF V600E-directed therapy (vemurafenib or dabrafenib, sometimes with trametinib) to symptom and scan improvement. Some reports included improvement in central nervous system (CNS) symptoms (the brain and spinal cord). These reports also described incomplete neurologic recovery in one patient with mixed LCH/ECD involving the CNS, and dose reductions or drug switching because of side effects in other individual reports (2026-1, 2026-3, 2026-5, 2026-6, 2026-9). Practical limits also showed up in individual reports. One report described grade 3 rhabdomyolysis (serious muscle breakdown) on dabrafenib plus trametinib that required dose reduction. Another highlighted that BRAF V600E immunostaining (a lab stain on biopsy tissue) could be equivocal/negative even when molecular testing (DNA-based mutation testing) confirmed the mutation (2026-9). In the reported real-world care, which targeted drug could be started and kept going often depended on having clear mutation testing and on close monitoring for tolerability.

Research covered in: January 2026, March 2026, May 2026, June 2026, September 2026

A defined subgroup gained comparative response data this year.

A more comparative treatment signal was reported for the specific subgroup of ECD with a co-existing myeloid neoplasm (a blood-forming bone marrow cancer). In a French cohort, kinase inhibitors were linked with higher ECD response rates at 6 and 12 months than pegylated interferon-alpha. Over 6 months, short-term myeloid neoplasm progression was reported at the same rate in both groups (2026-4). The same report noted shorter overall survival for people with both ECD and a myeloid neoplasm compared with ECD alone (2026-4). In this report, having both ECD and a blood disorder was repeatedly presented as a higher-risk situation overall, even when ECD responses to kinase inhibitors were high in the first year of follow-up described.

Research covered in: April 2026

Transplant moved from theoretical to reported, with mixed outcomes.

In the months covered, kidney transplantation moved from being discussed in theory to being described as an attempted option in a small number of ECD-related kidney failure cases. Outcomes ranged from years of graft function to deaths during follow-up (2026-2). In this small experience, infections were reported more than once. Imaging or tissue findings sometimes suggested ECD-related changes around the transplanted kidney months to years later. Treatment plans varied across patients, which limited clear conclusions about what drove better outcomes (2026-2). In the limited published experience, severe kidney involvement could lead to highly individualized care plans, where transplant was reported as feasible in some cases but came with substantial uncertainty and complication risk.

Research covered in: February 2026

Case reports emphasized rhythm risk even when scans improved.

Case-based reports in the months covered described cardiac ECD as both structural and electrical disease. Slow rhythms, heart block (a problem with the heart's electrical signal), and serious rhythm events were reported. Management in individual patients relied on detailed cardiac imaging and implanted devices (pacemakers/ICDs) (2026-8). One report described successful pacemaker placement despite right atrial and superior vena cava involvement, with normal function at 1 year. Another described ventricular fibrillation (a life-threatening irregular rhythm) despite reduced disease burden on vemurafenib, and the patient ultimately required an ICD (2026-8). In these reported cases, heart involvement sometimes led to urgent procedures and device-based treatment needs that were not necessarily resolved just because imaging showed improvement.

Research covered in: August 2026

More options appeared for biopsy, stains, and organ-specific imaging.

Across January 2026 to September 2026 reports, diagnosis was often described as a multi-step process. It combined imaging (often PET-based), biopsy interpretation, and mutation testing. Added stains such as cyclin D1 and pERK (special lab markers on tissue) and expanded mutation testing were reported as helpful when ECD mimicked other inflammatory/histiocytic conditions (immune-cell disorders that can look similar) or when classic bone findings were not present (2026-1, 2026-3). Several practical diagnostic options and comparisons were also reported. In a study of lung inflammatory myeloid neoplasms, including ECD and LCH, lung cryobiopsy (a freezing-based lung biopsy) often achieved diagnosis and sometimes enabled mutation testing, but it was less consistently diagnostic than surgical biopsy. A prospective imaging comparison in systemic histiocytoses, including ECD, suggested PET/MRI could add CNS lesion detail, while PET/CT performed better for lung lesions. Another report contrasted NaF-PET/CT (a bone-seeking PET scan) for osteosclerotic bone lesions with FDG-PET/CT (a sugar-uptake PET scan) for inflammatory activity changes after treatment (2026-6, 2026-7). Limits of testing were also described. These included an initially inconclusive pituitary-region biopsy later clarified on repeat biopsy, and BRAF V600E immunostaining that was faint/equivocal/negative despite molecular confirmation (2026-6, 2026-9). In these reports, getting to a firm diagnosis and choosing how to monitor disease often depended on picking a biopsy site that was feasible and selecting imaging and testing methods that matched the organs most affected.

Research covered in: January 2026, March 2026, June 2026, July 2026, September 2026